SCHEMBL26255163

SCHEMBL26255163

C1=CCC(CCNc2ncnc3c2ncn3C2CC2)CC1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ YTHDC1 Q96MU7 1/20 0.53
▸ ADORA2A P29274 4/20 0.44
▸ PI4KA P42356 3/20 0.40
▸ PI4K2B Q8TCG2 3/20 0.40
▸ PI4K2A Q9BTU6 3/20 0.40
▸ PI4KB Q9UBF8 3/20 0.40
▸ ADORA3 P0DMS8 3/20 0.40
▸ ADORA1 P30542 2/20 0.40
▸ ADORA2B P29275 1/20 0.40
▸ SLC29A1 Q99808 1/20 0.39
▸ CCNA2 P20248 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ CDK5 Q00535 1/20 0.38
▸ CDK5R1 Q15078 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24197147 0.88 YTHDC1 (0.55) YTHDC1ADORA2API4KAPI4K2BPI4K2A
SCHEMBL24197146 0.88 YTHDC1 (0.55) YTHDC1ADORA2API4KAPI4K2BPI4K2A
SCHEMBL24197229 0.88 YTHDC1 (0.55) YTHDC1ADORA2API4KAPI4K2BPI4K2A
SCHEMBL24196755 0.83 ADORA2A (0.53) YTHDC1ADORA2API4KAPI4K2BPI4K2A
SCHEMBL24197135 0.76 YTHDC1 (0.64) YTHDC1ADORA2API4KAPI4K2BPI4K2A
SCHEMBL24197042 0.73 YTHDC1 (0.53) YTHDC1ADORA2API4KAPI4K2BPI4K2A
SCHEMBL24196378 0.70 YTHDC1 (1.00) YTHDC1ADORA2API4KAPI4K2BPI4K2A
SCHEMBL24197040 0.70 YTHDC1 (0.59) YTHDC1ADORA2API4KAPI4K2BPI4K2A
SCHEMBL24197145 0.68 YTHDC1 (0.56) YTHDC1ADORA2API4KAPI4K2BPI4K2A
SCHEMBL24708227 0.66 YTHDC1 (0.88) YTHDC1ADORA2API4KAPI4K2BPI4K2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279006-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION KLOTHO THERAPEUTICS, INC. 2023-09-07 — — US disclosed
US-20230279006-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION KLOTHO THERAPEUTICS, INC. 2023-09-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279006-A1 NOVEL COMPOUNDS AND METHODS FOR INCREASING KLOTHO GENE EXPRESSION KLKB1, KLK2, KLK1 YTHDC1 2838/4885ADORA2A 2475/4885PI4KA 1999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback